WIRE - Novel Treatments in Renal Cell Cancer
Evaluation of proof of mechanism with relation to ktrans and/or CD8 count when different IMPs are given as monotherapy or as combination therapy. These would be administered in the "window of opportunity", prior to nephrectomy in surgically resectable renal cell cancer
Aged ≥18 years and over. [+26]
cT1a N0 M0-staged Renal Cell Cancer [+56]